The Pulmonary Fibrosis Foundation (PFF) and the U.S. Food And Drug Administration will discuss data from a survey requested for the Patient-Focused Drug Development Meeting For Idiopathic Pulmonary Fibrosis, to be held on the 26th of September on the FDA’s White Oak Campus. According to the information…
News
The Coalition for Pulmonary Fibrosis (CPF), which has chosen September as National Pulmonary Fibrosis Month, recently announced this year’s activities for increasing advocacy and awareness for the disease. According to the organization, the initiative, now in its 12th year, intends to raise awareness of the disease and…
While a major population of pulmonary hypertension patients are diagnosed with idiopathic or arterial pulmonary hypertension, a population of patients with pulmonary hypertension patients due to sarcoidosis is no less affected by the condition. Estimates from a paper published in Seminars in Respiratory and Critical Care Medicine state that…
A new study, entitled “The Sphingosine Kinase 1 / Sphingosine-1-Phosphate Pathway in Pulmonary Arterial Hypertension” conducted at University of Illinois’s College of Medicine, at Chicago, published in the American Journal of Respiratory and Critical Care Medicine, by Dr. Jiwang Chen, research assistant professor of critical care…
A new study published in August’s issue of Cardiovascular Research, entitled “Ranolazine prevents INaL enhancement and blunts myocardial remodeling in a model of pulmonary hypertension” suggests ranolazine (RAN) as a potential therapeutic agent in the treatment of PAH pathology. Pulmonary arterial hypertension (PAH) is a result of…
Pulmonary hypertension is a life-threatening, progressive disease that, to this day, is still incurable. Recently, a team of researchers turned to nature for answers, experimenting with extracting a protective enzyme from plant leaves that may hold the key to making a novel treatment work. Lead author and assistant…
The Maryland chapter of the Pulmonary Hypertension Association (PHA) recently announced that it is hosting a presentation on Emergency Preparedness for Pulmonary Hypertension Patients, via their Facebook page, which is taking place on Tuesday, September 23rd at 10 pm. The event is designed to help educated patients on…
Every Breath Counts: Idiopathic Pulmonary Fibrosis, a documentary to mark Pulmonary Fibrosis Awareness Month, will air on the Discovery Channel on September 13th and 27th at 8:00 am ET/PT. Supported by Boehringer Ingelheim Pharmaceuticals, Inc. and created together with the Pulmonary Fibrosis Foundation and the Coalition for Pulmonary Fibrosis, the…
Pulmonary Arterial Hypertension (PAH) is a life-threatening disease in which endothelial dysfunction, vasoconstriction in small pulmonary arteries, dysregulated proliferation of vascular cells, and dysregulated inflammatory signaling leads to pulmonary arterial obstruction increasing pulmonary vascular resistance and resulting in right ventricular failure. Different types of treatments for PAH exist that can…
Overwhelmingly positive results of Mast Therapeutics, Inc.‘s Phase 2 clinical trial of AIR001 (sodium nitrite, or Aironite®) inhalation solution for pulmonary arterial hypertension will lead to the company’s pursuit of additional Phase 2 trials in the near future. All doses of AIR001 were well-tolerated by patients and provided improvements…
Findings collected during more than two years confirming the safety and efficacy of Bayer’s Adempas® (riociguat) in treating either inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), and patients with pulmonary arterial hypertension (PAH) were recently presented at the European Respiratory Society (ERS) Congress. Riociguat is the first member of…
When Gilead Sciences, Inc. initiated a clinical trial for first-line combination therapy for pulmonary arterial hypertension treatment, the company felt that their ambitious approach to developing a new, viable therapy for the disease was worthy of the clinical trial name “AMBITION.” Now, according to a…
